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Background: Elevated intracranial pressure from cerebral edema is the major cause of early mortality in acute
stroke. Current treatment strategies to limit cerebral edema are not particularly effective. Some novel anti-edema
measures have shown promising early findings in experimental stroke models. Vasopressin antagonism in stroke is
one such target which has shown some encouraging preliminary results. The aim of this report is to highlight the
potential use of vasopressin antagonism to limit cerebral edema in patients after acute stroke.
Case presentation: A 57-year-old Caucasian man with new onset diplopia was diagnosed with vertebral artery
aneurysm extending into the basilar circulation. He underwent successful elective vertebral artery angioplasty and
coiling of the aneurysm. In the immediate post-operative period there was a decline in his neurological status and
brain imaging revealed new midbrain and thalamic hemorrhage with surrounding significant brain edema. Treatment
with conventional anti-edema therapy was initiated with no significant clinical response after which conivaptan; a
mixed vasopressin antagonist was started. Clinical and radiological evaluation following drug administration showed
rapid clinical improvement without identification of significant adverse effects.
Conclusions: The authors have successfully demonstrated the safety and efficacy of using mixed vasopressin
antagonist in treatment of stroke related brain edema, thereby showing its promise as an alternative anti-edema
agent. Preliminary findings from this study suggest mixed vasopressin antagonism may have significant utility in
the management of cerebral edema arising from cerebrovascular accident. Larger prospective studies are warranted to
explore the role of conivaptan in the treatment of brain edema and neuroprotection.
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Stroke is the fourth leading cause of death in United
States [1]. Brain edema and herniation are implicated in
the majority of these cases [2]. No effective agents exist
that have altered the management of brain edema to
the satisfaction of clinicians involved in stroke care.
Decompressive hemicraniectomy has reduced mortality
in malignant middle cerebral artery (MCA) stroke, but
only when used in younger populations within 48 hours
of symptom onset [3]. In the neurocritical care setting,* Correspondence: v.hedna@neurology.ufl.edu
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unless otherwise stated.mannitol and hypertonic saline are used extensively for
managing brain edema due to the lack of more effective
options, rather than its therapeutic superiority [4].
Significant controversy about the advantages and disad-
vantages of these agents in long term patient outcomes
following brain edema further complicate the clinical
picture [5]. Hence there is a great need for alternative
agents to rapidly decrease increased intracranial pres-
sure as a result of stroke-related brain edema, thereby
reducing brain herniation and its subsequent morbidity
and mortality.
Arginine-vasopressin (AVP), a potent endogenous hor-
mone responsible for regulating plasma osmolality and
volume, has demonstrated a role in the pathophysiologicalLtd. This is an Open Access article distributed under the terms of the Creative
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role in cerebral edema has made it a promising drug target
in the management of this condition [8]. Chang et al.
found time-dependent increases in serum AVP levels after
brain injury as well as attenuation of AVP levels following
administration of 7.5% hypertonic saline in an experi-
mental stroke model [7]. These studies also found that
osmotherapy is effective in reducing intracranial pres-
sure (ICP) through a common AVP-mediated pathway.
The mechanism of action of AVP is mainly mediated
by 2 receptor subtypes: V1a and V2 which are expressed
in the brain, pituitary gland, myocardium, vasculature
and kidneys. Experimental models have demonstrated the
utility of V1a and V2 AVP receptor antagonism in attenu-
ation of ischemia related cerebral edema and infarct vol-
ume by aquaporin (AQP) 4 expression modulation. Even
though appealing, the evidence for clinical utility of
vasopressin antagonism in stroke related brain edema
is sparse. Conivaptan is a mixed vasopressin receptor
(V1a and V2) antagonist that belongs to the group of
non-peptide vasopressin antagonists referred to as
“Vaptans” [9]. This class has been approved by Food
and Drug Administration (FDA) for use in hypervole-
mic/euvolemic hyponatremia [10].
We report a case of a disabling stroke after an endo-
vascular procedure who received conivaptan as last re-
sort to reduce his brain edema. This patient’s clinical
course and radiological findings were serially monitored
and recorded. Adverse events and safety data from this
medication were also monitored and documented.
Case presentation
A 57-year-old Caucasian male with residual right-sided
hemiparesis from a cerebrovascular event, 1 month prior
to this admission, presented with sudden onset of vision
changes. He complained his vision was “upside down”
with associated headache, nausea and vomiting. His past
medical history included pacemaker implantation, and
multiple sclerosis in remission. On neurological exam,
his National Institutes of Health Stroke Scale (NIHSS)
was 9 when including his previous residual neurological
deficits. Higher cognitive function was mostly intact
except for dysarthria, and diplopia on horizontal gaze
with right internuclear opthalmoplegia. His old deficits
from recent stroke included partial right facial palsy with
right hemiparesis (motor system examinations using the
Medical Research Council (MRC) grade: 2/5 in right
upper and lower extremity), hemi body numbness and
intact cerebellar function. Computed tomography (CT)
scan of the head without contrast revealed left precentral
gyrus hypodensity extending to the hand area, most
consistent with an evolving late subacute infarct corre-
sponding to the patient's right upper extremity weak-
ness. Most prominent was the finding of a partiallycalcified 16 mm fusiform aneurysm of the left vertebral
artery (VA) with extension to the basilar junction and
beyond. On day 1 of admission, he was complaining of
severe intractable headaches and depression. On day 6, he
had a sudden decline in his neurological exam wherein he
developed complete facial weakness, became somnolent,
and suffered a 25 minutes generalized tonic clonic seizure
(which was treated with a standard status epilepticus treat-
ment regimen). Repeat head CT demonstrated new hypo-
density in the mesial aspect of the left midbrain compared
to the admission study. This was most consistent with a
subacute infarct in the basilar perforator territory which
explained the patient's double vision.
Elective right vertebral artery angioplasty with aneurysm
stenting of the vertebral artery was performed on day 13.
Approximately 2 hours after the procedure his left pupil
became fixed and dilated. He developed dense hemiplegia
on his left side. Stat head CT demonstrated interval devel-
opment of acute hemorrhage in the mesial aspect of right
thalamus measuring 11 × 9 mm in maximal axial dimen-
sions. There was also hemorrhage seen in the central part
of upper midbrain measuring 8 × 8 mm. A significant
vasogenic edema surrounding the hematoma that ex-
tended up to the lower midbrain was seen (Figure 1A, B).
He was started on hypertonic saline with a target
serum osmolality of 300–320 mOsm/kg and serum
sodium goal of 150–160 mEq/L (post-operative sodium
was 140 mEq/L). On post-operative day 1, there was
no change in his neurological exam as the patient
remained unresponsive with left fixed, dilated pupil
and no movement on his left upper and lower extremity.
There was interval increase in the brain stem edema
in comparison to brain imaging from the previous day
(Figure 1C, D). Due to the lack of response from hyper-
tonic saline, he was started on intravenous conivaptan.
Conivaptan was administered as per the drug administra-
tion guidelines approved by FDA with 20 mg infused over
30 minutes as a loading dose, followed by a continuous
infusion of 20 mg over 24 hours (0.83 mg/hour) planned
for 2 days. On post-operative day 2, after 8 hours of
receiving the loading dose of conivaptan, patient started
responding to commands and was seen moving his left
upper and lower extremities. His sodium was 145 mEq/L.
In the next 2 days he was showing significant progress on
neurological exam, even demonstrating some strength
in his left upper extremity. Repeat head CT on day 18
(after 2 days of conivaptan administration) demonstrated
expected hematoma density changes both within the
mesial right thalamus and in the central midbrain, but
the size of the hematoma was stable compared to prior
examination. However, the perilesional edema had
significantly decreased, most apparent in the upper and
mid portion of the midbrain. The comparison of the
imaging at the level of both thalamus (Figure 2A, B) and
Figure 1 Imaging before conivaptan administration. The immediate post-procedure (intra-arterial stent insertion) CT head (without contrast)
demonstrate acute hemorrhage in the right mesial thalamus (A) with surrounding mild vasogenic edema and hypodensity on both sides of mid
brain (B). The CT head (without contrast) before conivaptan administration reveals slight decrease in the density of acute hemorrhage in the right
mesial thalamus, but with worsening surrounding vasogenic edema (C). The hypodensity in the mid brain has also worsened without any normal
density tissue visible, especially adjacent to the quadrigeminal cistern (D).
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of brain edema and restoration of some normal tissue
after conivaptan administration. Despite making signifi-
cant neurological improvements and tolerating extuba-
tion our patient subsequently developed respiratory
failure presumably due to aspiration pneumonia and his
family opted to shift to palliative care only.
Discussion
Conivaptan is a mixed vasopressin antagonist, currently
approved for euvolemic or hypervolemic hyponatremia
in heart failure, which has shown tremendous promise
in both experimental and clinical brain injury scenarios.
It acts via both V1a and V2 receptors making it the only
FDA approved mixed vasopressin antagonist [9]. There
is strong literature evidence to show V1a antagonism is
useful in limiting vasopressin mediated brain damage
after inducing stroke in animal models. The V1a antag-
onism was helpful in reducing brain edema via down-
regulation of AQP-4 in these experiments [11]. Since the
V2 receptor mediates AVP expression via positive feed-
back, V2 antagonism may, in theory, be advantageous
when formulating novel ligands for neuroprotection. In
the neurocritical care literature, conivaptan has beenused safely to reduce intracranial pressure, increase serum
sodium to desired goal, and to augment cerebral perfusion
pressure [12,13]. There is anecdotal evidence for its use
in neurosurgical and cardiac intensive care unit (ICU)
settings where it show promise in the treatment of hypo-
natremia secondary to traumatic brain injury and other
conditions [14,15]. The most common side effects de-
scribed for the short-term use of conivaptan include in-
fusion site phlebitis, headaches, increased thirst, pyrexia
and constipation. Orthostatic hypotension, hypokal-
emia, rebound hyponatremia, atrial dysrhythmias, and
sepsis are other serious adverse effects. Contraindica-
tions for using conivaptan are hypovolemic hyponatre-
mia and simultaneous use of CYP3A4 inhibitors [13].
During stroke, AVP is released from the posterior pitu-
itary in response to histamine activation of magnocellu-
lar neurons in the hypothalamus AVP then interacts
with its receptors V1a and V2 to mediate processes
which lead to further cerebral edema. Antagonism of
these receptors is described below:
Role of V1a receptors in brain
Vasopressin receptor V1a is involved in the pathogen-
esis of secondary brain damage following focal cerebral
Figure 2 Imaging after conivaptan administration. Comparative images at the level of thalamus pre (A) and post (B) conivaptan administration
shows significant reduction in vasogenic edema (red arrows) with normal density appearing tissue seen in the ventral aspect of right thalamus
following conivaptan administration (thick blue arrow). Moreover, comparative images at the level of mid brain pre (C) and post (D) conivaptan
administration clearly demonstrate significantly reduced hypodensity (red arrows), especially adjacent to the quadrigeminal cistern. The normal density
appearing tissue emerges following conivaptan administration (blue arrow heads).
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inhibition, AQP-4 channel modulation, reduced infarct
size and vasodilation. Also, V1a antagonists have been
shown to prevent the development of ischemia-induced
cerebral edema, thereby suggesting the importance of
the V1a receptor interaction in water regulation in
brain cells [16-18]. Further, vasopressin V1a receptor
antagonism has largely been shown to improve outcomes
after experimental stroke. A V1a antagonist SR49059, has
been demonstrated to decrease rates of brain water
accumulation at varying time points in intracerebral
hemorrhage (ICH) [19,20]. This agent also reduced
AQP-4 expression and led to decreased cerebral edema
after ICH. The aforementioned antagonist was found to
reduce cytotoxic brain edema via AQP-4 attenuation in
an experimental model of middle cerebral artery occlu-
sion (MCAO) [11]. Hence, it appears that AQP-4 chan-
nels, which play a key role in development of brain
edema, may be modulated by V1a antagonism [9]. Other
V1a antagonists have also shown similar effects in redu-
cing brain water content after cold-induced edema in
addition to dose-dependent decreases in the permeability
of the blood–brain barrier [8]. The V1a antagonism medi-
ated neuroprotection is postulated to occur via dampeningof cerebrovasodilation, caused by ATP-sensitive and
calcium-sensitive potassium channels, potentially leading
to decreased reperfusion injury and vasogenic edema [21].
Vakili et al. successfully demonstrated V1a antagonism
resulted in a dose-dependent attenuation of infarct volume
and blood–brain barrier disruption and more importantly
a decrease in brain edema [8].
Role of V2 receptors in brain
The V2 receptor expression in the central nervous sys-
tem is limited and the extent of its contribution in brain
edema is thus controversial [22]. Some studies demon-
strate V2 receptor antagonism may act by decreasing
AVP release through a negative feedback mechanism
[23,24]. Recently, a few studies have demonstrated that
the V2 receptor antagonist, OPC-31260, may be effective
in the early treatment of cytotoxic edema and brain
injury [18,25]. Administration of OPC-31260 amelio-
rated cerebral neurological deficit in transgenic mice
overexpressing endothelin-1 in astrocytes (GET-1) after
water intoxication. Treatment with OPC-31260 also
significantly decreased water accumulation and down-
regulated AQP-4 expression levels in GET-1 mice after
water intoxication. In fact, AQP-4 levels were shown to
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staining intensity in GET-1 mice with and without water
intoxication. It was also shown that administration of
OPC-31260 at doses of 10 to 30 mg/kg led to a dose-
dependent inhibition of subarachnoid hemorrhage-
induced cerebral edema formation, accompanied by an
increase in urinary volume and decrease in urine osmolal-
ity without a significant alteration of urine electrolytes
[26]. The V2 receptor antagonism also helped diminish
water accumulation, decreased glial fibrillary acidic pro-
tein (GFAP) in astrocytes, and most importantly led to a
renal tubule-selective diuretic effect called aquaresis (elec-
trolyte sparing diuresis), which may have additional bene-
fits in the reduction of cerebral edema [12].
To further explore the exciting promise of Conivaptan’s
use in stroke and brain edema, we have developed an ex-
perimental murine stroke model [27]. Early results from
this study have been promising. We have demonstrated
that conivaptan ameliorated brain swelling at two early
time points (12 h and 24 h) by more than 50% in compari-
son to control in MCAO. At 12 h, ipsilateral average
hemispheric edema (HE%) in the conivaptan-treated
group (n = 16) was 6.64 ± 1.62% versus 16.55 ± 1.76% in
controls (n = 16, p = 0.0003). This was reproduced at 24 h,
where HE% in the conivaptan-treated group (n = 12) was
6.81 ± 1.33% in comparison to 13.93 ± 1.57% in the control
group (n = 12, p = 0.002). Our studies are underway to
answer some questions about its mechanism of action in
attenuation of brain edema by concentrating specifically
on aquaporin channels and its ligands.
Conclusions
Brain edema contributes significantly to morbidity and
death associated with stroke. However current option
treatments are limited to hyperosmolar agents and surgical
decompression. In this case report we describe the poten-
tial of the mixed vasopressin antagonist, conivaptan, in the
acute treatment of brain edema. To our knowledge, this is
the first case report in the literature describing the benefits
of conivaptan use in clinical brain edema. Although this
report is very encouraging, additional randomized clinical
studies and caution is advised regarding its use until the
result of more definitive trials investigating its safety and
efficacy are known. We hope that this report highlights the
inadequacy of standard treatment of cerebral edema and
generates future studies which explore novel therapeutic
agents, including larger studies to fully characterize the
potential role of mixed vasopressin antagonism.
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